|
|
|
Dear [Full Name]
We are pleased to confirm your registration to view this Live Broadcast
on a new treatment option for adult patients with relapsed or refractory
diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.
Thank you for your participation!
For full Prescribing Information, Click Here
|
|
|
|
|
[Speaker 1 - Full Name, Credentials]
[Affiliation name]
[City, State /Country]
|
|
|
|
[Speaker 2 - Full Name, Credentials]
[Affiliation name]
[City, State /Country]
|
|
|
|
|
|
|
|
|
|
This Live Broadcast is sponsored by Karyopharm
Therapeutics Inc.
© 2020 Karyopharm Therapeutics Inc. All rights reserved.
US-XPOV-05/20-00030
|
|
|
|
|
Onclive – an MJH Life Sciences brand
Copyright 2020 © Intellisphere, LLC
2 Clarke Drive, Suite 100
Cranbury, NJ 08512
Preferences | Unsubscribe
|
|
|
